Sma Europe company information, Employees & Contact Information

Spinal muscular atrophy in the era of newborn screening: how the classification could change Frontiers

Roche’s Evrysdi tablet approved by European Commission as first and only for Spinal Muscular Atrophy (SMA) GlobeNewswire

Roche extends SMA market lead with Evrysdi tablet approval in Europe Pharmaceutical Technology

Roche’s Evrysdi tablets granted EC approval to treat spinal muscular atrophy PMLiVE

US, EU regulators to review higher-dose Spinraza for use in SMA SMA News Today

Addressing urgent gaps in care for adults living with SMA Roche

SMA announces further job cuts amid declining sales pv Europe

Meeting abstracts from the 12th European Conference on Rare Diseases and Orphan Products Orphanet Journal of Rare Diseases

Spinal Muscular Atrophy Update in Best Practices | Neurology Clinical Practice Neurology® Journals

SPINRAZA® (Nusinersen) Approved in the European Union as First Treatment for Spinal Muscular Atrophy Biogen

New gene therapy to treat spinal muscular atrophy (corrected) European Medicines Agency

Novartis has negotiated Zolgensma access for half of the European SMA population, exec says. How'd it get there? Fierce Pharma

Novartis gene therapy Zolgensma cleared for use in Europe BioPharma Dive

AveXis receives EC approval and activates “Day One” access program for Zolgensma®, the only gene therapy for spinal muscular atrophy (SMA) Novartis

Interview with Tasnim Jadwat, regarding access to treatments for SMA Knowledge Ecology International

European SMA Advocates Question EU’s Willingness to Reimburse for Zolgensma SMA News Today

Quantitative Tightening: How do shrinking Eurosystem bond holdings affect long-term interest rates? European Central Bank

Spinal Muscular Atrophy (SMA) screening for newborns in Europe Roche

Newborn screening and gene therapy in SMA: Challenges related to vaccinations Frontiers

Spinal Muscular Atrophy Update in Best Practices Neurology® Journals

Novartis cites 'transformative' data on Zolgensma as it rolls out SMA gene therapy in Europe Fierce Pharma

New Zolgensma 'inflection point' is here as Novartis snags EU nod for SMA gene therapy Fierce Pharma

The Birth Prevalence of Spinal Muscular Atrophy: A Population Specific Approach in Estonia Frontiers

Looking Ahead: How Consensus Guidelines Will Shape the Future of SMA Care NeurologyLive

SMA Solar Technology Powers Ahead as Europe’s Energy Transition Deepens TIKR.com

Comparing Enphase With Its European Competitor SMA Solar Technology AG (OTCMKTS:SMTGF) Seeking Alpha

Illuminating spinal muscular atrophy - update 2023 The Pharma Letter

Poland - Jan Stottko of SMA: “The most Polish inverter on the market” pv Europe

SMA Solar to slash jobs amid ‘persistently challenging’ residential PV market PV Tech

Novartis wins conditional EU approval for gene therapy Zolgensma Reuters

Fertility issues common in men with SMA, study finds SMA News Today

Man with SMA Sets off for European Backpacking Trip on His Friends' Backs People.com

Long-term Spinraza found safe, effective across SMA spectrum SMA News Today

Zolgensma (onasemnogene abeparvovec-xioi) for SMA SMA News Today

Survey of Monetary Analysts European Central Bank

Environment statistics at regional level European Commission

Long-term efficacy and safety of nusinersen in adults with 5q spinal muscular atrophy: a prospective European multinational observational study The Lancet

SMA Expert Arthur Burghes Calls for Universal Newborn Screening SMA News Today

Final positive results of Zolgensma® trial for SMA published European Pharmaceutical Review

A European Alliance for Newborn Screening in Spinal Muscular Atrophy AFM Téléthon

Drought impact on ecosystems in Europe European Environment Agency (EEA)

Data suggests SMA drug Zolgensma® has “significant therapeutic benefit” European Pharmaceutical Review

‘It’s a real-life Hunger Games’: a lifesaving drug costs $2m, but not every child can get it The Guardian

Raising SMN protein levels may be helpful early step in SMA treatment SMA News Today

Biogen Announces First Patient Treated in RESPOND Study Evaluating Benefit of SPINRAZA® (nusinersen) in Patients Treated With Zolgensma® (onasemnogene abeparvovec) Biogen

Efficacy and safety of gene therapy with onasemnogene abeparvovec in children with spinal muscular atrophy in the D-A-CH-region: a population-based observational study The Lancet

FDA Approval of Nusinersen for Spinal Muscular Atrophy Makes 2016 the Year of Splice Modulating Oligonucleotides Mary Ann Liebert, Inc.

SMA blockbuster Risdiplam tablet version receives approval in Europe ETPharma.com

Disinflation in the euro area European Central Bank

Economic Bulletin Issue 7, 2024 European Central Bank

Added benefit and revenues of oncology drugs approved by the European Medicines Agency between 1995 and 2020: retrospective cohort study The BMJ

SMA - The Peak 3 string inverter now with new functions pv Europe

An update on the accuracy of recent Eurosystem/ECB staff projections for short-term inflation European Central Bank

A dataset for monitoring agricultural drought in Europe - Scientific Data Nature

SMA Solar inverter sales and income mirrors ‘declining’ residential, C&I markets PV Tech

Environment statistics at regional level European Commission

ECB surveys European Central Bank

Zolgensma: Whatever happened to the world’s most expensive drug? SWI swissinfo.ch

Population screening and cascade testing for carriers of SMA Nature

News - ANA SMA highlights Afghan lead at European NCO summit DVIDS

European companies cut jobs amidst difficult economy, weak demand Business Standard